Left ventricular hypertrophy and clinical outcomes in hypertensive patients (Q37147735)

18 August 2017

1 reference

title

Left ventricular hypertrophy and clinical outcomes in hypertensive patients (English)

1 reference

left ventricular hypertrophy

18 August 2017

0 references

1 reference

Luis M Ruilope

1

0 references

Roland E. Schmieder

series ordinal

2

object named as

Roland E Schmieder

1 reference

18 August 2017

13 March 2008

1 reference

Journal of Clinical Hypertension

18 August 2017

1 reference

18 August 2017

21

1 reference

18 August 2017

5

1 reference

18 August 2017

500-508

1 reference

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

18 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

The assessment of left ventricular hypertrophy in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Normalization for body size and population-attributable risk of left ventricular hypertrophy: the Strong Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Prevalence of left ventricular hypertrophy and cardiac arrhythmias in borderline hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Prognostic value of 24-hour blood pressure variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Twenty-four-hour heart rate and blood pressure are additive markers of left ventricular mass in hypertensive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Renin-angiotensin system and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Association of plasma renin activity and echocardiographic left ventricular hypertrophy with frequency of new coronary events and new atherothrombotic brain infarction in older persons with systemic hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Left ventricular hypertrophy in hypertension: its arrhythmogenic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Relation of Left Ventricular Mass and Geometry to Morbidity and Mortality in Uncomplicated Essential Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Prognostic implications of left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Prognostic significance of left ventricular mass change during treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Left ventricular hypertrophy reversal and prevention of diabetes: two birds with one stone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Direct renin inhibitors: the dawn of a new era, or just a variation on a theme?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Analysis and interpretation of 24-h blood pressure profiles: appropriate mathematical models may yield deeper understanding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Relation of arterial structure and function to left ventricular geometric patterns in hypertensive adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study e

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

A point-score system for the ECG diagnosis of left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Prevalence of left ventricular hypertrophy in a hypertensive population

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Blood Pressure Variability and Organ Damage in a General Population

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Impact of the time rate of blood pressure variation on left ventricular mass

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

The role of non-haemodynamic factors of the genesis of LVH

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Plasma renin activity could be a useful predictor of left ventricular hypertrophy in essential hypertensives

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Left ventricular adaptation to hypertension and plasma renin activity

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Do we understand why regression of left ventricular hypertrophy is beneficial?

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

VALIDD should not invalidate angiotensin-receptor blockers

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Blood pressure independent association of microalbuminuria and left ventricular hypertrophy in hypertensive men

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Microalbuminuria is associated with unfavourable cardiac geometric adaptations in essential hypertensive subjects

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Arterial wall thickening at different sites and its association with left ventricular hypertrophy in newly diagnosed essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Relationship between left ventricular hypertrophy and renal and retinal damage in untreated patients with essential hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.16

7 January 2021

Identifiers

DOI

10.1038/AJH.2008.16

1 reference

18 August 2017

1 reference

PubMed ID

18437140